* Findings suggest drug may not impair memory, attention
* Merck's sleep drug now before FDA
CHICAGO, April 3 (Reuters) - A study in rats and monkeys suggests an experimental Merck & Co sleep drug may help induce sleep without causing the memory loss and attention problems sometimes seen in the commonly used drugs Ambien and Lunesta, company researchers said on Wednesday.
Experiments in animals suggest Merck's sleep drug Suvorexant, now before the U.S. Food and Drug Administration, may avoid these side effects, the company said.
Insomnia affects about 10 percent of U.S. adults, and roughly a third of these individuals take drugs to help them sleep. Most sleep aids, including Sanofi's Ambien or Sunovion Pharmaceuticals' Lunesta, act on a key neurotransmitter in the brain called GABA.
"These treatments work by forcing the brain to go to sleep," said study leader Jason Uslaner of Merck in an interview on the website of Science Translational Medicine, which published the study.
GABA receptors are important to many brain regions, including those important for cognition, which is likely why common sleep aids can cause memory loss and attention problems.
"When you hit those, you don't just hit the sleep system," John Renger, executive director and head of neruoscience basic research at Merck and one of the study's authors, said in a telephone interview.
Suvorexant is part of a class of drugs called Dual Orexin Receptor Antagonists or DORAs, which work by blocking chemical messengers called orexins. Orexins are responsible for keeping people awake. Levels of this compound rise during the day and fall at night.
Orexins originate in a specific region of the hypothalamus, so targeting them may have less impact on other brain functions, Renger said.
For this study, the team wanted to find out what would happen if someone is awakened on this drug and has a very high level of it in their system.
"How impaired would they be?" Renger said.
To test this, the researchers did a series of experiments on rhesus monkeys and rats. First, the team trained monkeys to perform a common attention test in which they needed to respond quickly to a blinking light on a screen and remember what they touched. Monkeys given GABA inhibitors were much slower in responding to the prompt, and in some cases, missed it altogether, while monkeys given a potent orexin blocker called DORA-22 did not show these attention issues, Renger said.
The team also saw differences in a simple memory test in rats. Rats were first exposed to a colored object, and then later exposed to it again. Typically, rats that recall an object show less interest in it when they are shown it again.
In the study, rats given GABA blockers were less likely to recall the objects than those given DORA-22.
Emmanuel Mignot of Stanford University, who wrote a commentary on the study in the same journal, said the findings show promise.
"Are DORAs the perfect hypnotics? Only long-term use in large numbers of insomnia patients will reveal whether these drugs will be preferred to GABAergic hypnotics, and whether they produce rare complications, including narcolepsy-like symptoms in predisposed individuals," Mignot wrote.
So far, Merck has not seen any cases of narcolepsy, a sleep disorder marked by daytime sleepiness, in its late-stage clinical trials, Renger said.
The most common side effects from Suvorexant have been headache and sleepiness. No serious drug-related side effects have been reported.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.